Protein Summary
Gasdermin-D, N-terminal: Promotes pyroptosis in response to microbial infection and danger signals. Produced by the cleavage of gasdermin-D by inflammatory caspases CASP1 or CASP4 in response to canonical, as well as non-canonical (such as cytosolic LPS) inflammasome activators (PubMed:26375003, PubMed:26375259, PubMed:27418190). After cleavage, moves to the plasma membrane where it strongly binds to inner leaflet lipids, including monophosphorylated phosphatidylinositols, such as phosphatidylinositol 4-phosphate, bisphosphorylated phosphatidylinositols, such as phosphatidylinositol (4,5)-bisphosphate, as well as phosphatidylinositol (3,4,5)-bisphosphate, and more weakly to phosphatidic acid and phosphatidylserine (PubMed:27281216). Homooligomerizes within the membrane and forms pores of 10 - 15 nanometers (nm) of inner diameter, possibly allowing the release of mature IL1B and triggering pyroptosis (PubMed:27418190, PubMed:27281216). Exhibits bactericidal activity. Gasdermin-D, N-term ...more
- ENST00000262580
- ENSP00000262580
- ENSG00000104518
- ENST00000526406
- ENSP00000433209
- ENST00000615119
- ENSP00000482096
- ENSG00000278718
- ENST00000631751
- ENSP00000488012
- DFNA5L
- GSDMDC1
- DF5L
- DFNA5L
- FKSG10
- GSDMDC1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
histone modification site profile | 0.76 | ||
kinase perturbation | 0.76 | ||
transcription factor | 0.66 | ||
tissue | 0.61 | ||
tissue sample | 0.59 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 513.24 (req: < 5)
Gene RIFs: 87 (req: <= 3)
Antibodies: 126 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 513.24 (req: >= 5)
Gene RIFs: 87 (req: > 3)
Antibodies: 126 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 17
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drugs: 2